| December 2004 | ||||||
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 | |
| Nov Jan | ||||||
For more search options, please see the Advanced search form and the section of the User's Guide, Tips for Searching PULSE.
C H A N N E L S
• PULSE Home
Page
•
EXECUTIVE
EDITION
•
US News
•
Canada
News
•
UK News
•
New
Zealand News
•
Consumer
Advocacy
•
Health
Care Systems
•
Managed
Care/Medicaid
•
Co-occurring
Disorders
•
Clinical
studies
•
Pharmaceutical
News
•
Criminal
Justice Systems
•
Legislative
News
U S E R ' S G
U I D E
About
PULSE
PULSE Channels
Archives
Adding comments
Using the # link
Items that require registration
PULSE syndication
Tips for Searching PULSE
E M A I L S
U B S C R I P T I O N S
For WEEKLY summaries
of PULSE postings, see the weekly
email subscription form.
For DAILY mailings (powered
by Bloglet), please enter your e-mail address below:
PULSE ANNUAL No. 2
January 2003
Recent
Trends, Challenges and Issues in Funding Public Mental Health Services
in the US
March 2002
PULSE ANNUAL No. 1
October 2001
PULSE is powered by
Radio Userland.
© Bill Davis, 2000-2003.
![]()
Many FDA Scientists Had Drug Concerns, 2002 Survey Shows
Washington Post story - "Almost one-fifth of the Food and Drug Administration scientists surveyed two years ago as part of an official review said they had been pressured to recommend approval of a new drug despite reservations about its safety, effectiveness or quality. The survey of almost 400 scientists also found that a majority had significant doubts about the adequacy of federal programs to monitor prescription drugs once they are on the market, and that more than a third were not particularly confident of the agency's ability to assess the safety of a drug. The results of the survey, conducted by the Department of Health and Human Services' inspector general, appear to support some portions of the controversial Senate testimony last month by FDA safety officer David J. Graham." [Viewing Washington Post stories requires registration, which is free.]![]()